Home > Boards > US OTC > Biotechs >

WPD Pharmaceuticals Inc (CNSX:WBIO)

CNSX:WBIO RSS Feed
Add CNSX:WBIO Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 4/14/2021 8:37:32 AM - Followers: 5 - Board type: Free - Posts Today: 0


WPD PHARMACEUTICALS













https://www.wpdpharmaceuticals.com/













OTCBB : $WCOTF

 





CORPORATE OVERVIEW

 
WPD Pharmaceuticals is a diverse biotech company that has 8 novel drug candidates with 4 that are currently in clinical trials today with ongoing
 
collaborations at MD Anderson Cancer Center, Mayo Clinic, Emory University, Wake Forest University and leading hospitals and academic centers in Poland.
 
Alongside direct investment of $60 million, over $29 million of grant funding (total of $89 million USD) has gone towards the development of our robust
 
drug development pipeline with a focus on melanoma, brain cancer, leukemia  and pancreatic cancer. Notably, these funds do not include $14 million USD in
 
grants recently awarded to WPD Pharmaceuticals from The National Centre for Research and Development in Poland.

  
With a groundswell of multi-continental grant support and a diverse portfolio of breakthrough drug technologies, WPD Pharmaceuticals is now strategically
 
positioned to enter the market with blockbuster potential.
 
 
 
 


 


CORPORATE PRESENTATION 

https://www.wpdpharmaceuticals.com/_resources/presentations/corporate-presentation.pdf
 


MANAGEMENT 



 



NEWS

 

WPD Pharmaceuticals Reports Active Compound in Licensed Drug Candidate

Reduces Coronavirus Replication in Vitro by 100%


To develop in collaboration with CNS Pharmaceuticals antiviral drug candidates licensed

from Moleculin Biotech for the international markets

Email Print Friendly Share
April 09, 2020 03:05 ET Source: WPD Pharmaceuticals
 
 

VANCOUVER, British Columbia, April 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical companyis pleased to announce that independent research on its WP1122 drug compound found 2-deoxy-D-glucose (“2-DG”) to reduce replication of SARS-CoV-2, the virus that causes COVID-19, by 100% in in vitro testing. WPD in collaboration with its development partner CNS Pharmaceuticals, Inc. (“CNS”)(Nasdaq: CNSP) intends to develop several preclinical drug candidates including WP1122, which will be tested on a range of viruses including the coronavirus SARS-CoV-2.

WPD has licensed rights to a portfolio of drug candidates, including WP1122, through its license partner, Moleculin Biotech, Inc. (“Moleculin”)(Nasdaq: MBRX). Recently, researchers at the University of Frankfurt disclosed the findings in their article submitted to NatureResearch on March 11, 2020 (Bojkova, D et al; DOI: 10.21203/rs.3.rs-17218/v1) (https://www.researchsquare.com/article/rs-17218/v1). The authors reported that inhibiting glycolysis with non-toxic concentrations of 2-DG completely prevented SARS-CoV–2 replication in Caco–2 cells.  Glycolysis is a process by which cells convert glucose into energy and infected (host) cells are induced by viruses to dramatically increase their dependence on glycolysis.  2-DG inhibits glycolysis because, although it appears to cells to be glucose, it is in fact a decoy that cannot be converted into energy.

WP1122 is referred to as a “prodrug” of 2-DG whereby chemical elements are added to 2-DG to improve its delivery in vivo.  Once administered, these added elements are removed by normal metabolic processes and what remains is 2-DG. As a result, 2-DG is the active compound in WP1122.  In chemical terms, it is referred to as the active “moiety” (subpart) of WP1122.

We are excited with this breakthrough on our WP1122 drug candidate and the early implications are that it could have positive effects on reducing the spread of COVID-19,” commented Mariusz Olejniczak, CEO of WPD. “I would like to commend our license partner, Moleculin and the researchers at the University of Frankfurt for their expedited work and the willingness of the authors to pre-release this data will help support our development of WP1122 for treating COVID-19.”

Walter Klemp, Chairman and CEO of Moleculin added: “This discovery essentially put our development efforts in to turbo-drive.  We are moving as quickly as we can to prepare WP1122 for clinical trials.  With the US and EU having established accelerated approval procedures for COVID-19 related projects, we expect this to move very quickly.  We look forward to WPD’s help, especially as it relates to expediting things in Europe.”

According to WPD’s license partner Moleculin, 2-DG is often referred to as the ‘active moiety’ in WP1122.  The issue with 2-DG is that its often metabolized too quickly by the body, so human tissues and organs can’t get enough concentration to be therapeutic.  Therefore, even though 2-DG is active against a range of viruses, including SARS-CoV-2, it isn’t useful as a clinical therapy because it metabolizes too rapidly.  WP1122 works to solve this problem because it is a ‘prodrug’ of 2-DG.  Its structure enables it to achieve much higher tissue/organ concentrations than 2-DG alone, but once it’s in the cell, it metabolizes into the exact same 2-DG that is so effective in vitro.

About WPD Pharmaceuticals

WPD is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules.  WPD has 10 novel drug candidates with 4 that are in clinical development stage. These drug candidates were researched at institutions including the Mayo Clinic and Emory University, and WPD currently has ongoing collaborations with Wake Forest University and leading hospitals and academic centers in Poland.

WPD has entered into license agreements with Wake Forest University Health Sciences and sublicense agreements with Moleculin Biotech, Inc. and CNS Pharmaceuticals, Inc., respectively, each of which grant WPD an exclusive, royalty-bearing sublicense to certain technologies of the licensor. Such agreements provide WPD with certain research, development, manufacturing and sales rights, among other things.  The sublicense territory from CNS Pharmaceuticals and Moleculin Biotech includes 31 countries in Europe and Asia, including Russia.

On Behalf of the Board

‘Mariusz Olejniczak’

Mariusz Olejniczak
CEO, WDP Pharmaceuticals

Contact:

Investor Relations
Email: investors@wpdpharmaceuticals.com
Tel: 604-428-7050
Web: www.wpdpharmaceuticals.com





 
CNSX:WBIO
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#111   $WPDPF: WP1066 makinezmoney 04/14/21 08:37:32 AM
#110   Good morning. Apparently this stock is a threebabiesbusy 02/05/21 09:15:31 AM
#109   https://finance.yahoo.com/news/wpd-pharmaceuticals-licensor-announces-100-123000433.html WPD Phar threebabiesbusy 02/05/21 08:56:58 AM
#108   Could anyone say something about the drugs in coffee2go 01/21/21 04:27:54 PM
#107   WPD Pharmaceuticals + Moleculin Biotech = WP1122 Blockbuster? coffee2go 01/16/21 10:33:57 AM
#106   7 Penny Stocks on a Tear Right Now coffee2go 01/16/21 07:45:12 AM
#105   Great news!! coffee2go 01/14/21 09:10:34 AM
#104   https://www.globenewswire.com/news-release/2021/01/14/2158540/0/en/WPD-Pharmaceu TheHasi 01/14/21 08:54:37 AM
#103   WPD Pharmaceuticals Contracts Clinigen Clinical Supplies Management to coffee2go 01/14/21 08:49:39 AM
#102   Great Video! WPC is mentioned! coffee2go 01/13/21 02:19:19 AM
#101   https://www.docwirenews.com/docwire-pick/home-page-picks/john-climaco-ceo-of-cns TheHasi 01/12/21 12:56:19 PM
#100   https://www.docwirenews.com/docwire-pick/home-page-picks/john-climaco-ceo-of-cns TheHasi 01/12/21 12:55:57 PM
#99   https://www.docwirenews.com/docwire-pick/home-page-picks/john-climaco-ceo-of-cns TheHasi 01/12/21 12:54:48 PM
#98   @money$hot: Thanks but die you read this? Money $hot 01/10/21 04:59:21 PM
#97   @money$hot: Thanks but die you read this? coffee2go 01/10/21 01:49:35 PM
#95   New drug reduces coronavirus replication in vitro by 100% coffee2go 01/10/21 09:10:57 AM
#94   WPD's phase 1 and 2 clinical trials on coffee2go 01/09/21 04:40:05 PM
#93   WPD holds the rights of WP1122 for 20 coffee2go 01/09/21 08:59:42 AM
#92   Anyone else here? coffee2go 01/09/21 06:56:00 AM
#91   Proud to be in under 0,50 :-) coffee2go 01/08/21 10:11:29 AM
#90   Yes, I think we are going straight up coffee2go 01/08/21 09:47:51 AM
#89   How far can we get? WP1122 reduces Coronavirus coffee2go 01/08/21 06:46:23 AM
#88   2 great stories this year: Berubicin and WP1122. coffee2go 01/08/21 03:11:59 AM
#87   Tenbagger 2021? WPD Pharma coffee2go 01/07/21 04:40:58 PM
#86   ? CSE: WBIO   WPD Pharmaceuticals Receives Second Prepayment of jejusk 09/16/20 10:13:21 AM
#85   When wpdpf gains the slightest traction it's going jejusk 08/11/20 10:48:55 AM
#84   Yep... Good stuff.. I think wpd is afraid jejusk 07/21/20 10:04:34 AM
#83   $WPDPF: Used to be $WCOTF.......... makinezmoney 07/21/20 08:21:49 AM
#82   Finally! Movement in the right direction jejusk 07/15/20 05:14:29 PM
#81   Is wpdpf ever going to gain some traction!?! jejusk 07/10/20 08:04:46 PM
#80   Thanks, mate. Perhaps we'll see some volume now! jejusk 07/05/20 10:28:07 PM
#79   Yes, your WCOTF shares will become WPDPF shares Renee 07/05/20 09:40:07 PM
#78   New event for me.. what happens to my jejusk 07/05/20 08:08:27 PM
#77   On the U.S. OTC WCOTF for WPD Pharmaceuticals Renee 07/02/20 07:12:38 PM
#76   News.. June 22.. for what it's worth.. https://www.wpdpharmaceuticals.com/news- jejusk 06/25/20 03:14:19 PM
#75   Are these guys going to bring this back jejusk 06/11/20 04:57:51 PM
#74   This on when Wcotf will get out of jejusk 05/29/20 11:29:36 AM
#73   Nice bump today.. Perhaps wpd will gain some jejusk 05/28/20 01:08:55 PM
#72   NEWS!! WPD Pharmaceuticals Licensor Granted Another Key Patent for jejusk 05/28/20 07:33:00 AM
#71   good luck. lucky,mydog 05/19/20 03:06:44 PM
#70   I'm thinking I'll be the proud owner of jejusk 05/19/20 03:06:10 PM
#69   there you go. a trade. lucky,mydog 05/19/20 09:42:18 AM
#68   it's now on the grey market. it's matched lucky,mydog 05/19/20 09:17:50 AM
#67   That's my question... considering this companys connections to jejusk 05/19/20 09:04:42 AM
#66   this didn't trade much before the suspension. lucky,mydog 05/19/20 08:51:22 AM
#65   I'm not sure how that impacts volume...we trade jejusk 05/19/20 08:36:16 AM
#64   it's a foreign company. lucky,mydog 05/19/20 08:33:00 AM
#63   I'm very surprised that this company isn't heavily jejusk 05/19/20 08:25:46 AM
#62   finra resumes trading. lucky,mydog 05/18/20 09:08:56 AM
#61   So this won't begin trading until July? Is jejusk 05/17/20 09:06:17 AM
PostSubject
Consent Preferences